D. Griffin

Lysophospholipids are potential biomarkers of ovarian cancer.

Rebecca Sutphen, Martin Martino, Hector Arango, 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Influence of specialty on pathology resource use in evaluation of cervical dysplasia.

M. Hoffman, D. Griffin, D. Shackelford, 1999, Obstetrics and gynecology.

Accuracy of pelvic examination in the assessment of patients with operable cervical cancer.

R. Cardosi, J. Fiorica, M. Hoffman, 2004, American journal of obstetrics and gynecology.

Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management.

R. Cardosi, J. Fiorica, M. Martino, 2005, American journal of obstetrics and gynecology.

The "dented bladder": diagnosis of a retroperitoneal hematoma.

C. Chambers, D. Griffin, R. K. Omarzai, 1995, Catheterization and cardiovascular diagnosis.

Superior vena cava syndrome during chemotherapy for stage 3c fallopian tube adenocarcinoma.

M. Martino, M. Hoffman, D. Griffin, 2004, Gynecologic oncology.

Radical trachelectomy.

D. Griffin, M. Hoffman, 2003, American journal of obstetrics and gynecology.

A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma

L. Puls, D. Griffin, C. Schammel, 2010, Medical oncology.

Transvaginal Cystectomy for Complete Bladder Prolapse

H. Ahmed, D. Wood, D. Griffin, 2012 .

Acute arterial occlusion in a patient with recurrent cervical cancer

M. Hoffman, D. Griffin, 2003 .

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.

T. Werner, P. Rose, M. Sill, 2015, Gynecologic oncology.

A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma

L. Puls, D. Griffin, C. Schammel, 2010, Medical oncology.